{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Investigational
Source:
NCT00028873: Phase 2 Interventional Completed Breast Cancer
(2001)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
LANIQUIDAR is a P-glycoprotein inhibitor. It was used in trials studying the treatment of breast cancer.
Class (Stereo):
CHEMICAL (ABSOLUTE)
LASINAVIR, a hydroxyethylene derivative, is highly specific human immunodeficiency virus (HIV) protease inhibitor with an IC50 of 1 nM. Its clinical development was discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Nupafant (BB-960) is a potent platelet activating factor antagonist that is active both orally and intravenously. Nupafant was in phase I clinical trials in the UK for the treatment of ischemia-reperfusion injury, however this compound has since been suspended.
Status:
Investigational
Source:
NCT00093275: Phase 2 Interventional Completed Spinal Cord Injury
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Nerispirdine, an acetylcholine release enhancer and a K+/Na+ use-dependent channel blocker, was in clinical development with sanofi-aventis for the treatment of multiple sclerosis. Nerispirdine is not proconvulsant. It can inhibit axonal K(+) channels and this mechanism may underlie the ability of the drug to enhance neuronal conduction. Nerispirdine can also inhibit neuronal Na(+) channels, a mechanism that may explain why nerispirdine lacks proconvulsant activity.
Status:
Investigational
Source:
NCT01399164: Not Applicable Interventional Completed Vitamin B-12 Deficiency
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Entasobulin (ZEN-012; AEZS-112) is a small molecule with several mechanisms of action, such as DNA fragmentation via inhibition of topoisomerase II as well as inhibition of tubulin polymerization. It exerts antineoplastic activity. It was being developed for the treatment of cancers.
Status:
Investigational
Source:
NCT02265289: Phase 1 Interventional Completed Healthy
(1999)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Lefradafiban, an orally active prodrug of fradafiban, is a novel glycoprotein (IIb/IIIa) inhibitor for the treatment of unstable angina. The pharmacokinetic and pharmacodynamic properties of lefradafiban were assessed in 130 healthy male volunteers who received a single dose of 10, 50, 75, 100, or 150 mg or multiple doses of 25, 50, 60, 75, 90, or 100 mg three times daily for one week. After both single and multiple doses, receptor occupancy and plasma lefradafiban levels correlated with platelet aggregation. Lefradafiban had been in phase II clinical trials by Boehringer Ingelheim for the treatment of thrombosis. However, it has been terminated.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Dutacatib is cathepsin K inhibitor developed by Novartis which reached a Phase I osteoporosis trial. Dutacatib reversibly binds to the catalytic site of cathepsin K, blocking substrate binding and subsequent cleavage. In preclinical models of breast cancer bone metastasis, treatment and preventive protocols with the cathepsin K inhibitor dutacatib (AFG495) alone or in combination with ZOL decreased tumour-induced osteolysis and skeletal tumour burden and did not affect primary breast tumour growth.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
IRTEMAZOLE is a uricosuric agent exhibiting a rapid uricosuric effect in normouricemic as well as in hyperuricemic persons.
Class (Stereo):
CHEMICAL (ACHIRAL)
Foropafant is a platelet-activating factor (PAF) antagonist which was developed by Sanofi. It was in clinical development for the treatment of asthma, thrombosis and ulcerative colitis. The development of the drug was discontinued due to lack of efficacy.
Class (Stereo):
CHEMICAL (ACHIRAL)
Acetiamine (syn. thianeurone or diacetamine) is a thiamine derivative which is rarely used in pharmaceuticals. It is lipid-soluble. It has been studied for the treatment of rheumatic diseases.
